{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/seborrhoeic-dermatitis/diagnosis/clinical-features/","result":{"pageContext":{"chapter":{"id":"1f674962-dade-5ce5-9b92-60820da005f7","slug":"clinical-features","fullItemName":"Clinical features","depth":2,"htmlHeader":"<!-- begin field f966eb4b-0d1b-4830-9874-593ae1a79f5f --><h2>What are the clinical features of seborrhoeic dermatitis?</h2><!-- end field f966eb4b-0d1b-4830-9874-593ae1a79f5f -->","summary":"","htmlStringContent":"<!-- begin item 09b8451e-164e-47fd-854c-049ce634c130 --><!-- begin field 37ccb803-140d-4031-bc1d-7ce5aa19e884 --><p><strong>In adolescents and adults:</strong></p><ul><li><strong>Seborrhoeic dermatitis is characterised by:</strong><ul><li>Relatively well defined patches of erythema associated with flaking of the skin; scales may be white or yellow, oily or dry.<ul><li>In darker skin affected areas may appear hypo or hyperpigmented compared to surrounding skin.</li></ul></li><li>Symmetrically distributed lesions — usually one or two body areas are affected but signs may be more widespread.</li><li>Mild itching (in particular where the scalp is affected).</li></ul></li><li><strong>The most commonly affected areas are the:</strong><ul><li>Scalp — lesions can range from mild desquamation (dandruff) to thick brownish crusts adherent to skin and hair.</li><li>Face (in particular the nasolabial folds, glabellar area, eyebrows, and behind the ears).<ul><li>The eyelids may be red, swollen and flaky (seborrhoeic blepharitis).</li><li>Inflammation may occur in the ear canals, the cup of the ear and behind the ears.</li><li>Seborrhoeic dermatitis in the beard area can present similarly to that on the scalp.</li></ul></li><li>Upper chest and back — different forms of seborrhoeic dermatitis may be apparent:<ul><li>Petaloid type — in men petal-shaped lesions typically develop on the presternal area.</li><li>Pityriasiform type (less common) — generalized macules and patches that resemble extensive pityriasis rosea.</li></ul></li><li>Flexures and skin folds (in particular axillae, groin, anogenital area, infra-mammary area and umbilicus).<ul><li>Maceration and intertrigo can develop in skin creases; in large flexures, the skin can appear glazed and pink.</li></ul></li></ul></li><li>Severity varies markedly from person to person — some people may only experience mild dandruff, whereas others have more widespread, oily, dense scaling.<ul><li>The possibility of HIV infection should be considered in people who present with severe or widespread seborrhoeic dermatitis.</li></ul></li><li>Images of seborrhoeic dermatitis can be found on <a data-hyperlink-id=\"8262ef5c-6e7a-45e2-98d3-a9fe00bd3f71\" href=\"http://www.dermnetnz.org/\">www.dermnetnz.org</a>.</li></ul><p><strong>In infants:</strong></p><ul><li>Infantile seborrhoeic dermatitis most frequently occurs between the third and eighth weeks and usually resolves by 6–12 months.</li><li>It occurs commonly on the scalp as cradle cap, but the face, ears, neck, or flexural folds may also be affected:<ul><li>On the scalp, the scales are yellow-brown, large and greasy; elsewhere, they are drier and appear smaller and whiter, and the rash appears as well-defined areas of erythema and scaling with tiny vesicles.</li><li>On the scalp and in the flexures, the eruption is confluent, but in other places, the rash starts as small, round, and oval areas which extend to form patterns.</li><li>Some (but not all) cases of nappy rash are thought to be associated with seborrhoeic dermatitis.</li></ul></li><li>Usually, the infant is well and itching is relatively mild — sleep is generally unaffected.</li><li>Generalized seborrhoeic dermatitis can occur but is uncommon in an otherwise healthy child.<ul><li>If generalized or severe seborrhoeic dermatitis is present in a child, <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/background-information/causes/\">underlying causes</a> including immunosuppression should be considered.</li></ul></li><li>Images of seborrhoeic dermatitis can be found on <a data-hyperlink-id=\"b4a04405-bd7f-4f01-9f7f-a9fe00bd40fc\" href=\"http://www.dermnetnz.org/\">www.dermnetnz.org</a>.</li></ul><!-- end field 37ccb803-140d-4031-bc1d-7ce5aa19e884 --><!-- end item 09b8451e-164e-47fd-854c-049ce634c130 -->","topic":{"id":"b328d01a-a44a-57e1-8920-22321b4c6c8b","topicId":"67c69cb5-e030-443e-802f-758ce0fe90f8","topicName":"Seborrhoeic dermatitis","slug":"seborrhoeic-dermatitis","lastRevised":"Last revised in February 2019","chapters":[{"id":"2c32aabf-f751-57c2-9fb1-bfd7e4c7e58d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96bfb0b4-09f0-5525-aaf3-ca2354a87cb4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9bf8c16e-f128-5c6a-b6e8-d4223dcf2346","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"debcdac6-7ef3-5820-90b8-353614354fc7","slug":"changes","fullItemName":"Changes"},{"id":"32308918-ad23-5b7d-a1c5-7c7a4edf3e35","slug":"update","fullItemName":"Update"}]},{"id":"efc69a37-1a91-539d-b4ce-b1cfc1d48baf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"09ce3910-2aa3-537d-97db-f473bf3f3c99","slug":"goals","fullItemName":"Goals"},{"id":"37776aed-67d4-5001-8e82-0fec56ecaa71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2638b372-65f4-549c-9c2d-fff4cf1c933d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"df03f868-28e0-52a9-9f30-aecfccaa745c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bf290438-2d1b-5233-a43a-e3fe0cbccaab","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d66aeca6-f9ff-5104-94d3-d115d20ad7d1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f9559ed-2d1c-52f3-ae50-cb983d1b7c7c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025302eb-268d-585c-b9a4-d83b4dbb0e5b","slug":"definition","fullItemName":"Definition"},{"id":"43d0a434-92b2-5c53-b4bd-f8ab32a8c0a3","slug":"causes","fullItemName":"Causes"},{"id":"0f04315e-ba03-5be7-a5dc-c724c1e3fe90","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad49e37a-e725-5ad1-9e7b-f84a79627169","slug":"complications","fullItemName":"Complications"},{"id":"50cfb7dd-1ad7-5d22-9c7e-8472fb0af48c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f674962-dade-5ce5-9b92-60820da005f7","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f384b060-7f9e-593e-8a77-6bbf957fd0c4","slug":"assessment","fullItemName":"Assessment"},{"id":"2b98bc5c-ae88-522e-89c4-79e05d301c3f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","fullItemName":"Management","slug":"management","subChapters":[{"id":"ca5edad5-d74c-565f-b254-2c59bed62420","slug":"seborrhoeic-dermatitis-infants","fullItemName":"Scenario: Seborrhoeic dermatitis - infants"},{"id":"4172af9c-8f8b-5bcc-a160-ca83f520099c","slug":"seborrhoeic-dermatitis-scalp-beard","fullItemName":"Scenario: Seborrhoeic dermatitis - scalp and beard"},{"id":"ad81b0ed-2e0c-5a1d-a7a0-e823d40d7ca4","slug":"seborrhoeic-dermatitis-face-body","fullItemName":"Scenario: Seborrhoeic dermatitis - face and body"},{"id":"715da1f8-f458-5eec-96e8-85e22060d505","slug":"seborrhoeic-dermatitis-severe-or-widespread","fullItemName":"Scenario: Seborrhoeic dermatitis - severe or widespread"}]},{"id":"bac53cb4-0b97-5d4b-8ce4-07a9584a5e4f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"970b1e50-a3fc-503d-bbe8-29ecfa575d20","slug":"products-available-otc","fullItemName":"Products available OTC"},{"id":"9b1c8434-e7ce-5cd0-8c49-9e1076fbcecb","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"d35c5c70-d96b-5a9a-a708-2e051cf3cece","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"}]},{"id":"b5cb8438-116a-5790-9b0f-2a480c577056","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"03823e51-3fec-53db-8dde-3fbe6e94526c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"364fda13-808d-599d-84cd-2b31ed7d0d94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fd9a5e23-6ee9-503f-bbc4-7239d8555e0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1120e62a-fd06-536e-8caf-945332e36549","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"214850c4-e7af-5924-9a63-09325facd062","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bfa9b404-d181-55eb-a3b2-8da0ee4edb43","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5171db55-6873-590e-b670-2d66a4b1b1eb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"53351976-bb0e-5c17-a1c6-bae76ad491f8","slug":"basis-for-recommendation-af5","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 77fd6dea-e512-42da-a307-fb4e96e55aa0 --><h3>Basis for recommendation</h3><!-- end field 77fd6dea-e512-42da-a307-fb4e96e55aa0 -->","summary":null,"htmlStringContent":"<!-- begin item af59a87f-4ff5-4edd-8697-d3b80a3f72d0 --><!-- begin field 63bae51b-2422-436a-aef8-ddd164a39882 --><p>The information on the clinical features of seborrhoeic dermatitis is based on clinical guidance from the World Health Organisation <em>Evidence and recommendations on seborrhoeic dermatitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>], <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>] and the Primary Care Dermatological Society <em>Seborrhoeic eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>], and expert opinion from the British Association of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>], Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Kastarinen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Elgash, 2019</a>].</p><h4>Distribution of lesions</h4><ul><li>In adults, the most commonly affected areas are the face (88%), scalp (70%), upper trunk (27%), and limbs (1–2% of cases) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>].</li><li>Expert opinion varies on the distinction between infantile seborrhoeic dermatitis, atopic eczema and psoriasiform napkin dermatitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>].</li></ul><h4>Severity</h4><ul><li>Extensive severe seborrhoeic dermatitis is considered to be a marker of immunodeficiency in both children and adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>].</li></ul><!-- end field 63bae51b-2422-436a-aef8-ddd164a39882 --><!-- end item af59a87f-4ff5-4edd-8697-d3b80a3f72d0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}